What the evidence actually says about delay timelines

For many people with knee osteoarthritis, the question arrives at a specific moment: pain is bad enough that a surgeon has mentioned replacement, but the idea of major surgery — the recovery, the implant, the finality of it — prompts an obvious question. Can an injection buy more time, and if so, how much?

The honest answer is that delay duration is not a single figure. It varies considerably by injection type and, just as critically, by how far the arthritis has already progressed. Some treatments provide three to six months of meaningful symptom relief per course — enough to defer a decision, complete a physio programme, or get through a busy season at work. Others appear capable of pushing the timeline out by two to three years.

The most specific delay data currently available relates to intra-articular polyacrylamide hydrogel (iPAAG, marketed as Arthrosamid®). Published clinical outcome data puts the average delay at two to three years in carefully selected patients, supported by prospective studies at six months (Bliddal et al., J Orthop Res Ther, 2021) and twelve months (Bliddal et al., J Orthop Surg Res, 2024) confirming its safety and effectiveness profile. For hyaluronic acid (viscosupplementation), population-level evidence from a large US Health Claims Database analysis (Altman et al., PLoS One, 2015) associates repeated injection courses with meaningful delay of total knee replacement, though symptomatic benefit per course typically runs to three to six months.

Two factors matter as much as which injection is chosen: disease stage and patient selection. These determine whether a realistic window of months or years is even on the table — and that is where the next sections focus.

Which patients are genuinely suitable for injection-based delay

The delay timelines described above apply only when the joint is still a viable candidate for injection support — and not every painful knee qualifies.

Mild-to-moderate osteoarthritis, where the joint space is reduced but some cartilage remains and the structure is partially intact, is the appropriate clinical target. In this group, the mechanical environment is still capable of responding to a lubricating or cushioning agent, and there is enough joint architecture left to preserve. End-stage, bone-on-bone arthritis sits outside that window: when cartilage has been lost entirely, no currently available injection can bridge that deficit, and replacement is usually the more honest recommendation.

A useful caution when reading injection research comes from Nicholls et al. (Adv Ther, 2019), whose systematic review found that excluding end-stage patients from hyaluronic acid trials substantially inflates the apparent effectiveness figures. Studies that recruit only mild-to-moderate cases will always look more impressive than real-world outcomes across an unselected clinical population. This is not a reason to dismiss the evidence — it is a reason to read it carefully.

Younger, active patients with a focal cartilage defect rather than diffuse OA represent a meaningfully different subgroup. A collagen scaffold approach, which relies on the patient's own cells regenerating cartilage tissue over six to twelve months, is relevant here — but only where the defect is structurally mappable and the surrounding joint is sound.

In all cases, confirming OA stage and joint structure requires imaging and specialist assessment. Self-identifying as 'mild' or 'moderate' from symptom severity alone is not a reliable guide; a consultation that confirms partial joint preservation is, however, genuinely positive news — it means realistic delay options exist.

Arthrosamid® — the strongest long-duration delay evidence

Arthrosamid® sits apart from other injectable options for a specific structural reason: once injected into the joint, the polyacrylamide hydrogel integrates into the synovial membrane and remains there permanently. It does not degrade, is not metabolised, and does not need to be repeated on a course basis. That non-biodegradable persistence is what underpins the two-to-three-year delay window outlined earlier — and it is also the detail that requires the most careful patient selection.

The evidence base rests primarily on Bliddal et al.'s prospective studies: a six-month evaluation published in the Journal of Orthopaedic Research and Therapy (2021) and a twelve-month open-label follow-up in the Journal of Orthopaedic Surgery and Research (2024), both confirming safety and sustained effectiveness for knee osteoarthritis. The BOA's healthcare professional materials describe the treatment as delivering 'safe and sustained pain relief with a single injection' — a meaningful contrast to the repeated three-to-six-month courses typical of hyaluronic acid. It is worth noting, however, that the two-to-three-year figure comes from published clinical outcome data rather than a randomised trial with time-to-replacement as its primary endpoint. The signal is consistent, but the evidence grade should be read in that context.

A secondary finding from Maulana, Cole and Lee (Journal of Arthritis, 2022) reported a reduction in patellofemoral bone marrow lesions following a single injection, raising the possibility that the effect extends beyond mechanical cushioning alone. Larger confirmatory trials are needed before that interpretation can be treated as established.

On safety, the non-biodegradable nature of the material is the principal caveat: complications are rare, but if they occur they may be more complex to manage than with an absorbable product. That is not a reason to avoid treatment in well-selected patients — it is a reason the decision warrants specialist imaging review beforehand.

Access is a practical constraint for most UK patients. Arthrosamid® is not funded by the NHS and is not covered by major private medical insurers. Private-pay costs run from approximately £3,000 for a single box to £8,000 for the full three-box protocol, inclusive of ultrasound guidance and follow-up. For many patients, that cost barrier is as significant as any clinical consideration.

Hyaluronic acid — population-level evidence for delaying surgery

Population-level data gives hyaluronic acid (HA) its strongest argument. Altman et al. (2015, PLoS One) analysed a large US Health Claims Database and found that patients who received HA injections were meaningfully less likely to proceed to total knee replacement during the study period — real-world evidence drawn from a scale that clinical trials rarely match.

The mechanism of delay is cumulative rather than singular. Each standard HA course typically provides three to six months of symptomatic benefit, so delay is built up over repeated courses rather than from a single long-lasting treatment. Current practice has shifted towards single high-molecular-weight formulations — Durolane and Monovisc are the most widely used examples — which replicate multi-injection efficacy in a single appointment, reducing the treatment burden for patients. The foundational evidence for HA viscosupplementation rests on Bellamy et al.'s 2006 Cochrane review and Concoff et al.'s 2017 systematic review and meta-analysis, which together established that multiple injection courses outperform single injections on efficacy measures, even as single-shot formulations have narrowed that gap in everyday practice.

The appropriate target population is mild-to-moderate OA — the staging question already established earlier in this article. HA has limited benefit when cartilage loss is complete.

For patients and referring clinicians assessing risk–benefit, HA's principal strengths are its longer evidence track record, broader clinical familiarity across the UK, and substantially lower cost than newer injectables. The Altman data is genuine and the population-level delay signal is meaningful; the calibrated expectation is simply that maintaining that delay requires ongoing treatment rather than a one-time intervention.

ChondroFiller® — a regenerative scaffold for focal cartilage defects

The two approaches covered above address osteoarthritis — a diffuse, progressive loss of cartilage across the joint surface. ChondroFiller® is designed for a fundamentally different structural problem: a focal cartilage defect, meaning a discrete, mapped area of damage within an otherwise reasonably intact joint.

Rather than lubricating or cushioning the existing surface, ChondroFiller® is a sterile type I/III collagen scaffold injected directly into the defect site under ultrasound guidance. The patient's own cells migrate into the scaffold and lay down new cartilage matrix over six to twelve months — a regenerative process rather than a symptomatic one. That distinction matters clinically. The treatment is not relieving pain by reducing friction; it is aiming to restore the structural integrity of a specific lesion.

The patient profile it suits is correspondingly narrow: typically younger and more active, with a focal chondral or osteochondral lesion and a joint that is otherwise structurally sound. In that context, the 'delay' framing shifts slightly — ChondroFiller® is not delaying osteoarthritis progression so much as addressing a discrete defect that, left untreated, might develop into broader joint deterioration requiring more extensive surgery.

Diffuse cartilage loss or end-stage OA sits outside its regenerative scope. The mechanism distinguishes it clearly from viscosupplementation and space-filling hydrogels; the indications barely overlap. Long-term randomised trial data are limited, and outcomes should be interpreted accordingly — successful cartilage regeneration in a well-selected patient is the goal, but it is not guaranteed.

When injection delay reaches its limit — and surgery becomes the right pathway

Knowing when to move on is as clinically important as knowing whether to start. No injection — whether a mechanical hydrogel, a viscosupplement, or a regenerative scaffold — reverses osteoarthritis, regenerates diffuse cartilage loss, or alters the underlying structural joint surface. The NHS positions injection therapies explicitly as a step within the treatment pathway, not a permanent endpoint: when pain is severe and function is substantially impaired despite conservative and injection-based management, joint replacement becomes the appropriate conversation.

One practical consideration for patients approaching that point concerns timing. Intra-articular injections administered within a certain period before total knee arthroplasty (TKA) have been associated with an increased risk of post-operative infection (Clin Orthop Relat Res 2017;475:45–52). This is not a reason to avoid injections during the delay phase — it is a reason to plan openly. A patient who may need surgery within a foreseeable window should discuss that possibility with a specialist before booking a further injection, so that both timelines can be managed together rather than in isolation.

The clearest signal that the injection window is closing is persistent or worsening pain despite adequate treatment, combined with imaging that shows advanced joint deterioration. At that stage, a specialist reassessment to review surgical options is not a concession — it is the right next step. Injection therapy and surgical planning are not mutually exclusive pathways; the most useful thing a patient can do when approaching that boundary is to have an honest assessment of where they are.

1. [1] Knee replacement - NHS. https://www.nhs.uk/conditions/knee-replacement/ https://www.nhs.uk/conditions/knee-replacement/